CDT Equity Inc.
CDT Nasdaq Pharmaceutical Preparations Financials FY2022โFY2025
Last close ยท Oct 23, 2026
$0.13
0.1%What CDT Equity Inc. does
No business description yet.
- Legal name
- CDT Equity Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Apr 15, 2026
- Accession ยท CIK
- 0001493152-26-016858
0001896212
Revenue and margins
CDT Equity Inc. had โ of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
CDT Equity Inc. returned $0.1M to shareholders in fiscal 2025. The diluted share count rose 11,000.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably CDT Equity Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.3M | $8.4M | $1.2M | $1.5M |
| Interest coverage | โ31.6x | โ | โ481.8x | โ183.8x |
| Current ratio | 0.2x | 3.2x | 0.3x | 0.3x |
| Quick ratio | 0.2x | 3.2x | 0.3x | 0.3x |
| Total assets | $0.0M | $7.2M | $4.2M | $5.7M |
| Total liabilities | $10.1M | $7.7M | $11.0M | $12.8M |
| Shareholders' equity | โ$10.1M | โ$0.5M | โ$6.8M | โ$7.2M |
| Net debt (โ = net cash) | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | โ / 6 | โ / 6 |
| Accruals ratio | โ52,420.0% | 198.9% | โ142.2% | โ480.9% |
| Altman Z'' | โ15,900.70 | โ6.49 | โ60.54 | โ93.53 |
4 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | $0.0M | $0.1M | $3.4M | $5.1M |
| Operating income | โ$3.2M | โ$5.3M | โ$15.4M | โ$36.8M |
| Interest expense | $0.1M | $0.0M | $0.0M | $0.2M |
| Pretax income | $0.8M | โ$0.5M | โ$17.8M | โ$39.2M |
| Income tax | $0.4M | โ | โ | โ |
| Net income | โ$4.9M | โ$0.5M | โ$17.8M | โ$39.2M |
| Net income to common | โ$4.9M | โ$0.5M | โ$17.8M | โ$39.2M |
| Diluted EPS | โ$0.13 | โ$8.92 | โ$61,598.62 | โ$1,177.89 |
| Diluted shares | 0.04B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||
| Cash from operations | โ$2.3M | โ$7.7M | โ$9.7M | โ$15.6M |
| Capital expenditure | โ | โ | $0.1M | โ |
| Free cash flow | โ | โ | โ$9.7M | โ |
| Depreciation and amortization | โ | โ | $0.0M | โ |
| Stock-based compensation | โ | $0.2M | $1.6M | $2.2M |
| Share buybacks | โ | โ | โ | $0.1M |
| Dividends and buybacks | โ | โ | โ | $0.1M |
| Balance sheet | ||||
| Cash and short-term investments | $0.3M | $8.4M | $1.2M | $1.5M |
| Current assets | $0.6M | $5.7M | $2.7M | $4.4M |
| Current liabilities | $4.2M | $1.8M | $10.7M | $12.8M |
| Property and equipment, net | โ | โ | $0.0M | $0.3M |
| Intangible assets | $0.0M | โ | โ | โ |
| Total assets | $0.0M | $7.2M | $4.2M | $5.7M |
| Total liabilities | $10.1M | $7.7M | $11.0M | $12.8M |
| Shareholders' equity | โ$10.1M | โ$0.5M | โ$6.8M | โ$7.2M |
| Returns | ||||
| Return on capital employed | 75.8% | โ97.0% | 235.5% | 512.6% |
| Return on assets | โ97,740.0% | โ14.8% | โ311.9% | โ797.0% |
| Growth | ||||
| Share count change | โ | โ98.2% | โ100.0% | 11,000.0% |
| Financial health | ||||
| Interest coverage | โ31.6x | โ | โ481.8x | โ183.8x |
| Current ratio | 0.2x | 3.2x | 0.3x | 0.3x |
| Quick ratio | 0.2x | 3.2x | 0.3x | 0.3x |
| Quality scores | ||||
| Altman Z'' | โ15,900.7 | โ6.5 | โ60.5 | โ93.5 |
| Accruals ratio | โ52,420.0% | 198.9% | โ142.2% | โ480.9% |
Source: SEC EDGAR XBRL filings (CIK 0001896212). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
